Table 1.
Summary of viruses and associated experimental parameters used in the first part of the study.
| Animal number | Sex | Virus stock | Dose (TCID50) | Route of infection | Plasma viral load (copies/mL) | Peripheral CD4 T cells (cells/μL) | Plasma LPS (EU/mL) | Plasma LBP (mg/mL) | Group |
|---|---|---|---|---|---|---|---|---|---|
| G1005V | ♀ | SHIV- 1157ipd3N4 |
50 | IV | <100 | 606 | 0.310 | 9.554 | MThigh |
| G1006V | ♀ | 50 | IV | 291 | 1271 | 0.105 | 2.667 | MTlow | |
| G1007V | ♀ | 50 | IV | <100 | 2271 | 0.095 | 4.327 | / | |
| G1008V | ♀ | 5 | IV | <100 | 2172 | 0.310 | 9.554 | MThigh | |
| G1009V | ♀ | 5 | IV | 327 | 867 | 0.125 | 6.649 | / | |
| G1010V | ♀ | 5 | IV | <100 | 592 | 0.095 | 1.952 | MTlow | |
|
| |||||||||
| G1011V | ♀ | SHIV-KB9 | 500 | IV | 13240 | 1277 | 0.525 | 7.309 | MThigh |
| G1012V | ♀ | 50 | IV | <100 | 674 | 0.095 | 4.879 | / | |
| G1013V | ♀ | 5 | IV | <100 | 866 | 0.100 | 5.515 | / | |
| G1014V | ♀ | 1000 | IV | 411 | 1287 | 0.085 | 2.562 | MTlow | |
|
| |||||||||
| G1015R | ♀ | SHIV- 1157ipd3N4 |
20 | IR (repeated 4) | 289 | 1931 | 0.140 | 4.718 | / |
| G1016R | ♂ | 20 | IR (repeated 4) | 660 | 875 | 0.085 | 2.590 | MTlow | |
| G1017R | ♂ | 20 | IR (repeated 6) | 1387 | 978 | 0.090 | 2.177 | MTlow | |
| G1018R | ♂ | 20 | IR (repeated 5) | 772 | 2707 | 0.105 | 5.988 | / | |
| G1019R | ♀ | 20 | IR (repeated 4) | 13555 | 431 | 0.545 | 9.554 | MThigh | |
| G1020R | ♀ | 20 | IR (repeated 10) | <100 | 2075 | 0.110 | 2.351 | / | |
| G1021R | ♀ | 20 | IR (repeated 10) | <100 | 1093 | 0.090 | 3.317 | MTlow | |
| G1022R | ♀ | 20 | IR (repeated 4) | 185 | 1869 | 0.090 | 6.195 | / | |
| G1023R | ♂ | 20 | IR (repeated 13) | <100 | 1446 | 0.615 | 7.058 | MThigh | |
| G1024R | ♂ | 20 | IR (repeated 10) | 2776 | 3127 | 0.850 | 9.554 | MThigh | |
IR: intrarectal; IV: intravenous; LBP: lipopolysaccharide-binding protein; LPS: lipopolysaccharide, MT: microbial translocation; SHIV: simian human immunodeficiency virus.